AVITA Therapeutics Sees Prelim. Q4 RECELL System Sales $3.79M, Total Net Revenue $3.88M

Preliminary Unaudited Results for Three Month Period Ended June 30, 2020 With effect from July 1, 2020, the Company is reporting financial results in United States dollars (US$), and prepared in accordance with U.S.

Benzinga · 2020-07-09 12:09

Preliminary Unaudited Results for Three Month Period Ended June 30, 2020

With effect from July 1, 2020, the Company is reporting financial results in United States dollars (US$), and prepared in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP).

  • U.S. RECELL® System Sales:
    • US$3.79M in the fourth quarter versus $3.78M in the third quarter, or an increase of 0.2%.
    • To compare with the Company's previously reported results (as reported under International Financial Reporting Standards (IFRS)):

      • U.S. RECELL System sales were US$3.88M (A$5.95M) in the fourth quarter versus US$3.86M (A$5.81M) in the third quarter, or an increase of 0.6% (2.4%).

  • Total global net revenue for the fourth quarter (unaudited):
    • US$3.88M in the fourth quarter, a decrease of US$0.06M or 1.6% over the US$3.94M recognized during the previous quarter.
    • To compare with the Company's previously reported results (as reported under IFRS) fourth quarter net revenue was approximately A$6.08M, versus A$5.96M in the third quarter, or an increase of 2.0%.

  • Cash and Cash Equivalents:
    • At the end of the fourth quarter, the Company had cash of approximately US$73.84M, a decrease of US$5.92M or 7.4% over the US$79.76M held at the end of previous quarter (inclusive of more than US$1M expended during the quarter on redomiciliation and preparation for U.S. GAAP compliance).
    • To compare with the Company's previously reported results (as reported under IFRS) cash at the end of the fourth quarter was A$107.02M, a decrease of A$22.92M from the A$129.94M reported in the previous quarter, driven by A$14.28M attributable to the effect of movement in the exchange rates on cash, and A$8.64M in operating expenses.
  • Commercial metrics:
    • Estimated procedural volumes decreased by approximately 4% from the prior quarter.
    • New accounts added – 8.

    • Cumulative accounts with Value Analysis Committee (VAC) approval – 77.